SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic […]
Tag: BioCardia
BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery
SAN CARLOS, Calif., June 12, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the China National Intellectual Property Administration has recently issued the Company Patent No: ZL […]
Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class
PARIS and SAN CARLOS, Calif., May 23, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix™ Biotherapeutic Delivery System for cell therapy […]
BioCardia Reports 2019 First Quarter Financial Results and Business Highlights
SAN CARLOS, Calif., May 20, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2019 and filed its quarterly […]
BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart
SAN CARLOS, Calif., May 08, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AVANCE™ steerable introducer product family, […]
BioCardia Reports 2018 Financial Results and Recent Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities […]
BioCardia Submits 510(k) Application to FDA for AVANCE Steerable Introducer for Transseptal Access to Heart
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced its 510(k) submission for U.S. Food and Drug Administration (FDA) clearance of the AVANCE™ steerable introducer, designed for introducing various […]
Positive 12-Month Data on BioCardia’s Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018
CHICAGO & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive 12 month data for the roll-in cohort of its pivotal CardiAMP™ Heart Failure Trial studying the investigational CardiAMP […]
BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the […]
BioCardia Welcomes Cardiovascular Device Veteran Mark Schwartz as Vice President of Clinical Affairs
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia® [OTC: BCDA] today announced that Mark Schwartz, a 25-year veteran of cardiovascular device development, has joined the company as Vice President of Clinical Affairs, effective November 1. Schwartz brings extensive leadership experience in the design and […]